Business Segments · Investment income and other, net
Business Segments — Investment income and other, net
Neurocrine Biosciences Business Segments — Investment income and other, net increased by 8.9% to $28.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.5%, from $21.70M to $28.10M. Over 3 years (FY 2022 to FY 2025), Business Segments — Investment income and other, net shows an upward trend with a 180.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toInvestment income and other, net
How to read this metric
Higher values indicate effective management of cash reserves and potential for additional liquidity.
Detailed definition
Includes interest earned on cash and cash equivalents, as well as other non-operating income or expenses. This provides...
Peer comparison
Standard treasury metric; depends heavily on interest rate environments and cash balances.
Metric ID:
nbix_segment_reportable_segment_investment_income_and_other_netHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.03M | $1.03M | $1.03M | $1.03M | $13.20M | $13.20M | $13.20M | $13.20M | $22.30M | $22.80M | $23.40M | $22.50M | $21.70M | $20.60M | $22.20M | $25.80M | $28.10M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% | +0.0% | +68.9% | +2.2% | +2.6% | -3.8% | -3.6% | -5.1% | +7.8% | +16.2% | +8.9% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | +68.9% | +72.7% | +77.3% | +70.5% | -2.7% | -9.6% | -5.1% | +14.7% | +29.5% |
Range$1.03M – $28.10M
CAGR+128.8%
Avg YoY Growth+389.8%
Median YoY Growth+70.5%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — investment income and other, net?
- Neurocrine Biosciences (NBIX) reported business segments — investment income and other, net of $28.10M in Q1 2026.
- How has Neurocrine Biosciences's business segments — investment income and other, net changed year-over-year?
- Neurocrine Biosciences's business segments — investment income and other, net increased by 29.5% year-over-year, from $21.70M to $28.10M.
- What is the long-term trend for Neurocrine Biosciences's business segments — investment income and other, net?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — investment income and other, net has grown at a 180.3% compound annual growth rate (CAGR), from $4.10M to $90.30M.
- What does business segments — investment income and other, net mean?
- Income earned from cash reserves and other non-core business activities.